Faro Health Inc.
Faro Health Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Faro Health Inc..
Faro Health Inc. is a company.
Key people at Faro Health Inc..
Key people at Faro Health Inc..
Faro Health Inc. is an AI-powered software platform that optimizes clinical trial protocol design and execution for pharmaceutical and biotechnology companies. It serves sponsors, CRO ClinOps teams, research sites, vendors, patients, and laboratories by providing a unified digital infrastructure that standardizes study activities, delivers real-time insights, and automates workflows to reduce costs, timelines, and patient burden.[1][2][3][4] The platform addresses core challenges in clinical development, such as protocol complexity, amendments, and inefficiencies, enabling faster study startup with features like AI-driven optimization, document authoring, and EDC builds; it has demonstrated proven ROI, including over $300 million in potential cost savings and 200,000 patient hours avoided across users.[4]
Founded in 2019 and headquartered in San Diego, California, Faro has raised $35 million in funding ($15M Series A and $20M follow-on), expanded its leadership, and gained traction with leading biopharma teams, positioning it for growth in the digital transformation of clinical trials.[1][2]
Faro Health was founded in 2019 by Scott Chetham, Ph.D., who serves as Co-Founder and CEO, alongside co-founders including Patrick Leung as CTO. Chetham's background includes building companies that sell to large enterprises, providing deep experience in partnering with pharma giants, which directly shaped Faro's enterprise-focused strategy.[1][2] The idea emerged from recognizing inefficiencies in clinical protocol design—where poor planning leads to costly amendments, delays, and higher patient burdens—drawing on methods like those published by Chetham and colleagues to redesign schedules of assessment for optimal efficiency.[4]
Early traction came via its cloud-native platform, with pivotal funding rounds: a $15M Series A followed by $20M to scale digital infrastructure for smart clinical trials. The company strengthened its team, appointing executives like Kimberly C. Pospahala as VP of Commercial, and presented at industry events like SCOPE in 2022, accelerating go-to-market for protocol digitization.[2]
Faro stands out in clinical trial software through its AI-powered, end-to-end platform that connects the entire ecosystem for seamless protocol development and execution. Key strengths include:
These features deliver operational efficiency, with users reporting substantial savings in trial complexity and execution time.[1][4]
Faro rides the AI and digital transformation wave in clinical trials, where market forces like rising R&D costs (often exceeding $2B per drug), regulatory pressures for efficiency, and FDA ambitions for AI-driven data practices demand smarter infrastructure.[4] Timing is ideal amid post-pandemic trial decentralization and agentic AI advancements, enabling Faro to simplify modern designs—historically plagued by 30-50% amendment rates—and accelerate drug development for biopharma innovators from small biotechs to global pharma.[3][4][5]
By standardizing protocols as data, Faro influences the ecosystem through reduced patient burden, faster startups, and cost savings, fostering a shift to "smart clinical trials." It empowers collaborative decision-making, aligns functions, and sets a foundation for downstream AI automation, positioning it as a key enabler in a $50B+ clinical research market increasingly reliant on cloud-native tools.[1][2][5]
Faro is poised to dominate AI-enabled clinical development as biopharma scales agentic systems for end-to-end trial automation, with its platform evolving toward fully unified flows from design to operations. Trends like FDA data standardization and AI for revenue/marketing scale will amplify its impact, potentially capturing more market share through integrations and expanded ROI proofs.[1][3][4] Influence may grow via partnerships with top pharma, driving industry-wide protocol digitization and slashing global trial timelines by months.
This builds on Faro's core strength: turning protocol design from a bottleneck into a strategic accelerator for better studies.
